DMAC vs RIGL โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
RIGL Captures Institutional Edge (3โ1 Pillars ยท 10โ0 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Rigel Pharmaceuticals Inc. (New) (RIGL) driven by superior Valuation, Growth & Margin, Options & Structure while DMAC counters with relative strength in Momentum & Technical. Fundamentally, DMAC trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus RIGL at 9.3x Forward P/E and 26.3% operating margin (+16.5% YoY). In options structure, DMAC sits in SURGE (14th %ile IV; Dealer Gamma Walls on Pro) against RIGL sits in CONSOLIDATION (4th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | DMAC Revenue | RIGL Revenue | DMAC Op. Margin | RIGL Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $0M | $40M | -1352.2% | -163.3% | RIGL |
| FY2019 | N/A | $60M | N/A | -116.5% | RIGL |
| FY2020 | N/A | $110M | N/A | -26.7% | RIGL |
| FY2021 | N/A | $150M | N/A | -8.4% | RIGL |
| FY2022 | N/A | $120M | N/A | -46.2% | RIGL |
| FY2023 | N/A | $120M | N/A | -17.5% | RIGL |
| FY2024 | N/A | $180M | N/A | 13.5% | RIGL |
| FY2025 | N/A | $290M | N/A | 42.6% | RIGL |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | DMAC | RIGL | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $503.1M | $860.3M | Larger Scale | RIGL |
| Trailing P/E Ratio Valuation | N/M | 2.8x | Lower Multiple | RIGL |
| Forward P/E Ratio Valuation | N/M | 9.3x | Lower Multiple | RIGL |
| Revenue Growth (YoY) Growth | +0.0% | +16.5% | Higher Growth | RIGL |
| Operating Margin (TTM) Profitability | 0.0% | 26.3% | Higher Margin | RIGL |
| Net Profit Margin Profitability | 0.0% | 106.6% | Higher Margin | RIGL |
| Return on Equity (ROE) Capital Efficiency | -114.6% | 109.2% | Higher ROE | RIGL |
| 52-Week Range Position Momentum | 55% ($5โ$11) | 68% ($25โ$53) | Stronger Trend | RIGL |
| Beta / 30D Volatility Risk Regime | 1.74ฮฒ ยท 98% Vol | 1.05ฮฒ ยท 74% Vol | Lower Realized Risk | RIGL |
| Unified Institutional Score Composite Signal | 46.3 / 100 (HOLD) | 59.9 / 100 (HOLD) | Higher Composite | RIGL |